Thursday, 17 December 2015


Previous posts have featured articles from Dr Zhang research

and Prof Lewis research  on persister cells of Borrelia.

 Dr Horowitz has been working closely with these doctors to try to develop new approaches and claims to be having some success such that trials are due to be done shortly.
An earlier post on Dr Horowitz

So I was very interested to read a summary about a recent presentation from Dr Horowitz at a weekend conference, this is discussed at length on the Lymewhisperers blog

'Dr. Horowitz and Ying Zhang from John Hopkins, it seems, are on the verge of a breakthrough. Using mycobacterium drugs–like those used in leprosy and tuberculosis–in hope of cleverly and mercilessily attack the four main persisters: Borrelia, Babesia, Bartonella and mycoplasma. As Dr. Horowitz explains, he is typically successful in getting 92% of his patients better. But there is an “8%” that are the most difficult to treat. Could this breakthrough break the code for closing in on the 8% of people that are most difficult to get better? It could. I’ll never forget those chilling yet cheerful words: “We are closing in on the 8%,” Dr. Horowitz whispered.'

Go to the above link to read more and thank you to Lymewhisperer for sharing this important information with us.

Are Mycobacterium Drugs Effective for Treatment Resistant Lyme Disease, TickBorne Co-Infections, and Autoimmune Disease? 
Richard I. Horowitz* and Phyllis R. Freeman

No comments:

Post a Comment